You are here

  • Home
  • Archive
  • Volume 33, Issue 11
  • Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England

Citation Tools

Article menu
Original research
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Goulden S, Heffernan K, Sen Nikitas F, et al
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
International Journal of Gynecologic Cancer 2023;33:1715-1723.